Effect of silimarin on non-alcoholic fatty liver disease in children

Evaluation of the effect of silimarin in children with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015012520781N1

Enrollment

Registered

2015-04-04

Start date

2014-11-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: In the case group Silimarin capsule manufactured by Sabz Daroo company with dose of 140 mg three times a day is used for 3 months. Intervention 2: In the control group placebo capsul

Treatment - Drugs

Placebo

In the case group Silimarin capsule manufactured by Sabz Daroo company with dose of 140 mg three times a day is used for 3 months

In the control group placebo capsule filled with starch, made by the researcher is used three times a day for 3 months

Eligibility

Sex/Gender

All

Age

5 Years to 16 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Obese children with non-alcoholic fatty liver manifestations in ultrasonography. Exclusion criteria : Use of ethanol; use of hepatotoxic drugs; hepatitis B and C; autoimmune hepatitis; Wilson disease; Hemochromatosis; alpha-1 antitrypsin; severe coronary disease; severe lung disease; liver cirrhosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
AST. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;ALT. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;Fatty liver disease stage. Timepoint: Before and after the treatment. Method of measurement: Ultrasonography.;TG. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;HDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;LDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.	—

Measure

Time frame

AST. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;ALT. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;Fatty liver disease stage. Timepoint: Before and after the treatment. Method of measurement: Ultrasonography.;TG. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;HDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.;LDL. Timepoint: Before and after the treatment. Method of measurement: mg/dL.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHanieh Hajian, MD

Qom University of Medical Sciences

hhajian@muq.ac.ir+98 25 3612 2952

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026